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 Early life exposure to endocrine-disrupting chemicals or “obesogens” could predispose 
individuals to weight gain.  Acetaminophen (paracetamol) is the most common over-the-counter medication to treat 
pain and fever in pregnancy, and it has been suggested to exhibit hormonal effects in 
recent experimental studies thus a possible “obesogen” that should be evaluated for its 
potential to promote weight gain. Acetaminophen intake in the first 12 months of life was associated with higher child BMI 
at age 7 in a cross-sectional survey collected from 18 countries, and a case-control study 
of 25 obese children in the U.S. at age 3-5 years detected elevated levels of 
acetaminophen metabolites in umbilical cord blood.
 In this large population-based longitudinal study in Denmark, we found no consistent 
associations between maternal intake of acetaminophen during pregnancy and BMI z-
scores and waist circumferences in the offspring measured at age 7 and 11 years. We observed that frequent exposure to acetaminophen during pregnancy (i.e. indicated 
by intake in all three trimesters or higher cumulative weeks of use) was positively 
associated with overweight in girls at age 11, but not in boys.
What is already known about this subject?
What does this study add?
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 There was no strong evidence to suggest that prenatal exposure to acetaminophen may 
influence childhood BMI, but the observed association between frequent prenatal 
exposure to acetaminophen and overweight in girls warrant further investigation.  
ABSTRACT
Objective: Acetaminophen (paracetamol), a medication commonly used in pregnancy, has 
hormonal effects suggested in experimental studies. Developmental exposure to endocrine 
disruptors could predispose individuals to weight gain. We evaluated the associations between 
prenatal acetaminophen exposure and child’s overweight.
Methods: We studied 30,127 (age 7) and 24,934 (age 11) children in the Danish National Birth 
Cohort born during 1996-2002. Mothers reported acetaminophen use in telephone interviews 
conducted during pregnancy, and children’s body-mass-index (BMI) and waist circumference 
were reported by parents at 7 and 11 years. We estimated differences for BMI z-score and waist 
circumference, and risk ratio for overweight in girls and boys adjusting for indications of use and 
other confounders.
Results: We found no consistent associations for prenatal acetaminophen exposure and BMI z-
score or waist circumference in girls and boys at both ages. Prenatal acetaminophen exposure 
was associated with overweight in girls at age 11 (RR 1.31 (95%CI 1.10, 1.56) if exposed in all 
three trimesters and p-trend <0.001 for cumulative weeks of exposure), but no association was 
found in boys.  
Conclusions: There was no strong association between prenatal acetaminophen exposure and 
childhood BMI, but the findings on frequent prenatal exposure to acetaminophen and overweight 
in girls warrant further investigation.  
INTRODUCTION
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Acetaminophen (paracetamol) is a commonly used over-the-counter medication for pain relief 
and fever reduction. Unlike other antipyretics and analgesics, acetaminophen is not considered 
contra-indicated for pregnancy use and about 40-60% of pregnant women reported using 
acetaminophen at least once during pregnancy in the USA and in Western/Northern European 
countries (1). Acetaminophen can cross the placental barrier reaching the fetus who has limited 
capacity to metabolize acetaminophen during early development (2). Recent experimental 
studies have suggested that acetaminophen exhibits endocrine disruptive effects and in-utero 
exposure could affect fetal development (3, 4). Intrauterine exposure to acetaminophen inhibited 
fetal testosterone production in ex vivo fetal rat testes (4, 5), while female mouse fetuses exposed 
to acetaminophen showed perturbed proliferation of the primordial germ cells resulting in a 
reduction of ovarian follicle reserves (6). Epidemiological studies have also found that prenatal 
acetaminophen exposure was associated with increased occurrence of cryptorchidism (7) and 
shorter anogenital distance (8) in male infants, and earlier pubertal development in the female 
offspring (9). 
Emerging research have suggested that early life exposure to “obesogens”, 
including xenobiotic chemicals and endocrine disruptors, could permanently alter metabolic 
processes and predispose individuals to weight gain (10, 11, 12). Obesogens can cause weight 
gain by altering lipid homeostasis to promote adipogenesis and lipid accumulation, increasing 
the number and the size of adipocytes, or by altering the endocrine pathways responsible for the 
control of adipose tissue development (13). Acetaminophen is a possible “obesogen” that should 
be evaluated for its potential to promote weight gain (3, 4). Two epidemiological studies have 
previously suggested a possible link between early life exposure to acetaminophen and higher 
BMI in childhood (14, 15). The ISAAC study analyzed cross-sectional surveys collected for a 
total of 76,216 children in 18 countries found that acetaminophen use in the first 12 months of 
life was associated with higher BMI at age 7 in affluent countries (14). However, the study did 
not evaluate prenatal acetaminophen exposure, and the information on infant acetaminophen use 
was retrospectively reported by the parents when the child was 7 years old thus susceptible to 
recall bias. Moreover, a recent small matched case-control study conducted in the U.S. also 
reported elevated levels of acetaminophen metabolites in umbilical cord blood in 25 obese 
children at age 3-5 years compared to 25 sex-matched non-obese children (15). However, 
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acetaminophen has a short half-life thus a single measure of metabolites at birth might only 
indicate exposures shortly before delivery and do not represent exposure throughout pregnancy.
Here, we used longitudinal data collected in the Danish National Birth Cohort (DNBC) and 
evaluated the associations between maternal acetaminophen use in pregnancy and risks for being 
overweight in offspring at age 7 and 11 years. All analyses were stratified by boys and girls to 
evaluate potential sex-specific differences since earlier studies in the cohort reported sex-specific 
associations of prenatal exposure to acetaminophen and reproductive health outcomes in the 
offspring (7, 9).  
METHODS
Study population
The Danish National Birth Cohort (DNBC) is a nationwide longitudinal study of pregnancies and 
children (16). Briefly, women were recruited between 6–12 weeks of gestation from 1996 to 
2002 by about 50% of all general practitioners in Denmark. Among all pregnant women invited, 
60% agreed to participate. The data collection instruments and questionnaires of the DNBC can 
be found online at http://www.dnbc.dk. There were 100,417 eligible pregnancies in the DNBC 
and we restricted our analyses to live-born singleton children with both exposure and outcome 
data available. A total of 64,322 mothers completed the enrollment form and the three telephone 
interviews (approximately at the gestational weeks of 12 and 30, and 6 months after birth) where 
information on acetaminophen intake during pregnancy was collected. Among these, BMI and 
waist circumference data were available in 38,983 (61%) children at age 7 and 31,647 children 
(49%) at age 11 years. For this study, we further restricted the analyses to 30,127 children at age 
7 years and 24,934 children at age 11 years, excluding children if their height and weight 
measurements were taken for more than 3 months apart or if the timing of when the 
measurements were taken was missing.
Exposure assessment
At the first contact, women filled out an enrollment form that included questions regarding any 
supplement and medication use covering the period from four weeks before pregnancy until the 
gestational week of reporting. In the three computer-assisted telephone interviews, women were 
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asked to report whether they had taken any pain killers during pregnancy. Respondents who 
answered ‘yes’ were provided with a list of 44 common pain killers including acetaminophen 
whether available over-the-counter or via prescription. Additional questions also gave women 
the opportunity to report use of pain killers or drugs not specified in the list in an open-ended 
question. Women were asked to report the gestational week of use on a week-by-week basis. The 
information on weekly intake was used to calculate trimester specific and duration of use. The 
first, second and third trimesters were defined by the following time periods, weeks 1 through 12, 
weeks 13 through 24, and week 25 to delivery, respectively. We categorized the cumulative 
weeks of acetaminophen use into 1, 2-5, 6-20, and >20 weeks.  
Outcome measures
Information on children’s BMI and waist circumference were collected at 7 (mean and SD 7.05 
± 0.25) and 11 (mean and SD 11.30 ± 0.63) years of age. At age 7 years, 33% of these 
measures were taken by the school doctor, public health nurse, or the general practitioner, and 
for the remaining 67%, measurements were taken by one of the parents. Information on 
weight, height, and waist circumference at age 11 years was reported by the mother or father. 
The internal age- and sex-specific BMI z-scores were calculated using the Lambda, Median, 
Sigma (LMS) method (17). We categorized overweight at age 7 and 11 years according to the 
International Obesity Task Force (IOTF) reference (18). Since less than 1.5% of the children 
in the cohort were obese, overweight and obesity were combined and are referred to as being 
‘overweight’.
Covariates 
We used directed acyclic graphs to identify potential confounding factors a priori. First, we 
included demographic factors such as child’s birth year (categorical), maternal age at child birth 
(≤24, 25-29, 30-34, and ≥35 years), and parity (1st child, 2nd child, or more children) derived 
from the Danish medical birth register. Maternal pre-pregnancy BMI (continuous), maternal 
smoking (never, ≤9, and >9 cigarettes/day) and parental socio-occupational position were 
collected from the telephone interviews. A four-level socio-occupational variable was created 
based on the highest among maternal or paternal education and occupation: (1) high grade 
professional with extensive education, (2) medium grade professional with medium-length 
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education, (3) skilled worker or works in a position requiring less education, (4) unskilled worker, 
unemployed, or on financial assistance. To address possible confounding by indication, we 
controlled for three specific maternal conditions during pregnancy including maternal fever 
(yes/no), inflammation/infection (yes/no), and musculoskeletal diseases including pain (yes/no), 
as these conditions may trigger acetaminophen use (19) and also affect child development. 
Information regarding maternal diseases during pregnancy were reported by the mothers in the 
second phone interview during pregnancy. Moreover, we also controlled for the most commonly 
used nonsteroidal anti-inflammatory drugs including the over-the-counter drugs ibuprofen and 
acetylsalicylic acid (aspirin) to address potential confounding by other medication. Information 
regarding ibuprofen and aspirin use were collected in a manner similar to acetaminophen, as 
described above. 
Statistical Analyses
We used multivariable linear regression models to estimate the difference (β) of childhood 
BMI z-score or waist circumference (in cm) at age 7 and 11 years according to prenatal 
acetaminophen exposure (ever/never, trimester of use, and cumulative weeks of use) with never 
use as referent. We also used a generalized linear model to estimate the risk ratio (RR) for 
being overweight in childhood. We calculated p-value in linear-trend tests by fitting cumulative 
weeks of exposure as a continuous variable. We adjusted for the above mentioned potential 
confounders in all statistical models. Analyses were conducted for boys and girls separately to 
evaluate sex-specific exposure effects on the outcomes at these ages. Test for heterogeneity was 
also conducted by including an interaction term between prenatal acetaminophen exposure 
(ever/never) and child’s sex in the regression model. We performed additional sensitivity 
analyses restricting to mothers who did not experience fever, inflammation/infection, or 
musculoskeletal diseases and pain during pregnancy. Mothers who used acetaminophen for more 
than 30 weeks of gestation (<2%) were excluded in linear trend tests to evaluate the influence of 
extreme values. In addition, we adjusted for paternal BMI (reported by mothers when the child 
was 18 months old), maternal use of antibiotics and medications for sleep problems or 
depression in pregnancy to evaluate possible confounding by these factors. Multiple imputations 
were used to estimate the missing values of covariates (about 5% of participants were missing at 
least one covariate value).
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    To assess possible bias due to loss to follow-up, we first compared the characteristics of the 
mothers and children who did or did not participate at the 7 and 11 years follow up. Next, we 
utilized inverse-probability-weights (IPW) technique to account for possible selection bias. We 
modeled the probability of participation at 7 and 11 years follow up according to a range of 
measured factors available for all women in the DNBC at baseline. The list of factors found to be 
predictive of participation in the 7- or 11-year follow-up and included in the IPW is presented in 
the appendix (see appendix A and B). We incorporated the stabilized IPW in all regression 
analyses and computed the 95% confidence intervals (CIs) using robust variance estimators. In 
sensitivity analyses, we compared our results with and without implementing IPW. All statistical 
analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).      
RESULTS
Of the children in the 7- and 11-year cohorts, more than half (55%) of the mothers reported ever 
using acetaminophen during pregnancy (see Table 1 and Table S1). Acetaminophen use was 
more common among parous women, smokers, those with higher pre-pregnancy BMI, and who 
experienced fever, infection/inflammation and musculoskeletal diseases in pregnancy. Compared 
with the baseline cohort in the DNBC, the characteristics of mothers and children who 
participated in the 7- and 11-year cohorts were similar (see Table S1). There were some 
differences observed such as women who were generally healthier (i.e. having had a normal pre-
pregnancy BMI and did not smoke) and women from higher social classes were more likely to 
have participated in the follow-ups.
Overall, there was no strong association found between prenatal acetaminophen exposure and the 
continuous BMI z-scores and waist circumferences in girls and boys at both age 7 and 11 years 
(Table 2). Some sex-differences were observed that the effect estimates were mostly negative for 
boys and positive for girls (p-values for the interaction term between ever use of acetaminophen 
and child’s sex were <0.10 for these outcomes), but most of the confidence intervals were wide 
and included the null. No association was found for cumulative weeks of exposure and BMI z-
scores or waist circumference in girls and boys at both ages (Table S2).  
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We also found no associations between prenatal acetaminophen exposure and overweight in boys 
and girls at age 7 (Table 3). However, at age 11, we estimated that girls exposed to 
acetaminophen at least once had an elevated RR for overweight (RR=1.10 95%CI 0.97, 1.24), 
and a 31% higher risk for being overweight if the girls were exposed in all three trimesters 
(RR=1.31 95%CI 1.10, 1.56). The estimated RRs for exposure in the first and second trimester 
were higher than that in the third trimester, but the CIs were wide and overlapped. A linear dose-
response like pattern was detected for cumulative weeks of acetaminophen exposure in 
pregnancy and overweight in girls at age 11 (p-trend < 0.001) (see Figure 1). There was no 
association for prenatal acetaminophen exposure and overweight in boys at age 11.
Our findings did not change when restricting to women who did not experience fever, infections, 
musculoskeletal diseases and pain; the risks for overweight were elevated in girls at age 11 who 
were frequently exposed to acetaminophen during pregnancy among women who did not have 
these diseases or conditions (Table 4). The results were also remained consistent in sensitivity 
analyses additionally adjusted for paternal BMI, and maternal use of antidepressants and 
medications for sleep problems in pregnancy (Table S3) or when excluding the extreme heavy 
users (Table S4). The effect estimates changed minimally when comparing models with and 
without implementing IPW accounting for possible selection bias due to non-participation in the 
follow up (Table S5).
DISCUSSION
We did not find consistent associations between prenatal acetaminophen exposure and BMI z-
scores and waist circumferences in the offspring measured at age 7 and 11 years. However, we 
observed that frequent exposure to acetaminophen during pregnancy was positively associated 
with overweight in girls at age 11, but not in boys. 
Acetaminophen is considered a “safe” medication for pregnant women (20). The guideline of use 
has not been changed in spite of recent findings that suggested frequent use of acetaminophen in 
pregnancy might affect a range of adverse health outcomes in the exposed offspring, including 
reproductive toxicity (7, 21, 22), neurobehavioral disorders (19, 23, 24), asthma (25), and 
pubertal development (9). Elevated oxidative stress via the depletion of glutathione (26, 27) or 
interference on steroid hormone functions (4, 28, 29) are proposed as the shared underlying 
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biological pathways affecting multiple outcomes. Large-scale studies that evaluate additional 
potential long-term health consequences in the prenatally exposed offspring are urgently needed. 
Recently, a large cross-sectional study (the ISAAC study) based on data from 18 countries 
reported that acetaminophen use in the first 12 months of life was related to a small increase 
(~0.07 kg/m2) in the mean childhood BMI age 6-7 years in affluent-GNI countries only (14). A 
cross-sectional association between self-reported frequent acetaminophen exposure and higher 
BMI among adolescents aged 13-14 was also found but the direction of the association is unclear. 
Data collected from affluent countries in the ISAAC study might have a higher degree of 
accuracy, but it is also possible that the exposure-related weight promoting effects are more 
apparent in developed countries that follow high-calories and high-fat diets (12). The observed 
early postnatal exposure effect could be confounded by in-utero exposure, which has been 
suggested as a sensitive period for adiposity promoting effects in animals exposed to synthetic 
chemicals (12). 
Emerging evidence has indicated that in-utero exposure to “obesogens” (11, 12), including 
various types of endocrine disruptors, can disturb the developmental and homeostatic controls 
over adipogenesis thus affecting the weight-control mechanisms and energy balance later in life 
(10, 13). Prenatal exposure to pharmacologic sources of estrogenic agents such as oral 
contraceptives and diethylstilbestrol (DES) were linked to childhood overweight or obesity in a 
few studies (30, 31). Acetaminophen has been reported to induce rather strong hormonal effects 
such as inhibiting androgen or prostaglandin synthesis in experimental settings (4, 28, 29). 
Further experimental studies are needed to test the possible adiposity-promoting effect of 
acetaminophen and to elucidate the mechanisms of action.   
The positive association observed for girls at 11 years might indicate a sex-hormone specific 
mechanism of the exposures (32), but it could also be explained by the timing of pubertal growth 
and outcome measures in our study. Some girls might have started entering puberty at age 11 
while for most boys this is still considered a pre-pubertal period (33). Another DNBC study 
followed a subset of offspring up to age 16 found that prenatal acetaminophen exposure was 
associated with a 2-3 months earlier attainment of several markers of pubertal development (e.g. 
pubic hair, axillary hair, and acne) only in the female offspring (9). We only have complete BMI 
data at age 7 and 11 for this study preventing us to further explore growth trajectories and 
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account for pubertal development. Studies with longer follow-up time are needed to evaluate 
whether the estimated sex-specific exposure effects persist into older ages.
Our study has several strengths. First, the analyses were conducted using data from a large 
nationwide cohort of mothers and their children with up to 11 years of prospective follow-up. 
Secondly, the exposure information was recorded multiple times during pregnancy using 
structural telephone interviews and the women were provided with a list of medications which 
could assist with their reporting. Acetaminophen was mostly sold as a singular drug over-the-
counter in Denmark under 3 major brand names (Pamol, Pinex, and Panodil) at the time of the 
study which limited the challenges of having to estimate exposures for combination drugs that 
might be common in other countries (34). Moreover, the outcomes were recorded in a large 
group of offspring at two time points. Finally, we were able to control for a range of potential 
confounders in our analyses. Maternal pain and fever have been previously estimated to be the 
main indications for taking acetaminophen in pregnancy (19), but these factors are not 
demonstrated as risk factors for childhood obesity. Other types of NSAIDs were not 
recommended in Denmark for pregnant women during the study period thus the prevalence of 
use was much lower compared to acetaminophen. Controlling for NSAIDs as well as other 
medications such as antibiotics for infections and medications for sleep problems or depressions 
did not change our findings. 
Limitations of our study should be noted. The results could be affected by exposure and outcome 
misclassifications. Although the exposure information was queried multiple times with relatively 
short recall periods, it is possible that mothers have under-reported the use of this commonly 
used drug (35). Flawed recall of drug names, timing, and frequency of use was likely non-
differential to the outcome. We assessed the cumulative weeks of exposure but did not have 
information on the days of use and the exact number of pills and dosage taken which limited our 
ability to perform a true exposure dose-response analysis. Parent-reports of BMI might also be 
subject to errors. A previous validation study showed that the proportion of children 
categorized as overweight was slightly lower in the DNBC compared to our parent-reported 
BMI at age 7 with measurements by school doctors in a subgroup of children, but the degree 
of under-reporting was found to be consistent across the distribution of height and weight of 
the children (36). We do not expect our main findings to be solely driven by correlated 
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measurement errors otherwise we would expect a stronger association at age 7 but not at age 11 
in girls because the gaps between parental reports for the exposure and outcome are smaller. 
Overall, the estimated prevalence of childhood obesity is lower in Denmark compared with other 
European countries according to the WHO surveys (37) potentially limiting the generalizability 
of our findings to countries with higher rates of obesity.
Our analyses only included women who completed all interviews that collected acetaminophen 
use information at baseline. The proportion of overweight in the children at age 11 years (~8.7%) 
was comparable among women who did or did not complete all these interviews suggesting 
influence from selection bias at baseline is minimal. Nevertheless, influence from loss-to-follow-
up bias is possible since only about half of the children were included in the 11 year analyses. 
The direction of this bias is hard to predict, but we found that in general mothers and children 
who were healthier were more likely to have participated in the 11 year follow up. If the exposed 
and overweight children were more likely to drop out that might bias the results towards the null. 
IPW technique was used to minimize influence from drop out, but we cannot rule out residual 
biases from unmeasured factors that were not included in the model. Finally, we also cannot rule 
out possible influence from uncontrolled confounding. Acetaminophen is taken for a variety of 
reasons which could be mild or severe (19, 20). Some major indications of acetaminophen use 
such as fever, infections and musculoskeletal diseases and pain did not appear to explain our 
findings. Genetic factors may also play a role in childhood obesity (38), but it is unknown 
whether these genes also correlate with acetaminophen use in pregnancy. 
In summary, we analyzed a large national sample and did not find strong evidence to suggest 
maternal intake of acetaminophen during pregnancy affect BMI z-scores and waist 
circumferences in the offspring. However, we observed that maternal frequent use of 
acetaminophen was associated with an increased risk for overweight in girls at age 11 years, 
which warrants further investigation. 
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Table 1. Characteristics of study participants by exposure to acetaminophen at least once (ever/never) during 
pregnancy 
7 year cohort  11 year cohort
  Exposed 
(N=16,644)
Unexposed 
(N=13,483)
 Exposed 
(N=13,681)
Unexposed 
(N=11,253)
n % n % n % n %
Mother age (years)
≤ 24 1265 7.6 975 7.2 871 6.4 720 6.4
25-29 6248 37.5 5230 38.8 5118 37.4 4323 38.5
30-34 6450 38.8 5129 38.0 5418 39.6 4347 38.7
≥ 35 2681 16.1 2149 15.9 2274 16.6 1863 16.6
Parity
1st child 7228 43.4 6705 49.7 5719 41.8 5420 48.2
2nd or more child 8954 53.8 6378 47.3 7576 55.4 5477 48.7
Missing 462 2.8 400 3.0 386 2.8 356 3.2
Child's sex
Male 8582 51.6 7037 52.2 6730 49.2 5754 51.2
Female 8062 48.4 6446 47.8 6951 50.8 5499 48.9
Child's Birth year
1997-2000 10091 60.6 8128 60.3 7872 57.5 6459 57.4
2001-2003 6553 39.4 5355 39.7 5809 42.5 4794 42.6
Parental Socio-occupational status
1 (highest) 5716 34.3 5228 38.8 5093 37.2 4601 40.9
2 5546 33.3 4435 32.9 4637 33.9 3729 33.1
3 4742 28.5 3460 25.7 3535 25.8 2665 23.7
4 (Lowest) 590 3.5 327 2.4 387 2.8 227 2.0
Missing 50 0.3 33 0.2 29 0.2 31 0.3
Maternal drinking during pregnancy
Never 4342 26.1 3950 29.3 3423 25.0 3244 28.9
1-4 glass(es) per week 6622 39.9 5247 38.9 5624 41.1 4535 40.3
more than 4 glasses per week 5680 34.1 4286 31.8 4634 33.9 3474 30.9
Maternal smoking during pregnancy
Never 12224 73.4 10647 79.0 1047
4
76.6 9147 81.4
≤ 9 cigarettes/day 2175 13.1 1529 11.3 1687 12.3 1124 10.0
> 9 cigarettes/day 2245 13.5 1307 9.7 1520 11.1 982 8.7
Mother pre-pregnancy body mass index
<18.5 558 3.4 581 4.3 515 3.8 494 4.4
18.5-25 11046 66.4 9634 71.5 9396 68.7 8293 73.8
26-29 3363 20.2 2278 16.9 2571 18.8 1765 15.7
≥30 1444 8.7 788 5.8 1022 7.5 544 4.8
Missing 233 1.4 202 1.5 177 1.3 157 1.4
Fever during pregnancy 5515 33.1 2999 22.2 4532 33.1 2492 22.2
Missing 9 0.1 4 0.0 5 0.0 4 0.0
Musculoskeletal diseases and pain during 
pregnancy
2166 13.0 1126 8.4 1631 11.9 843 7.5
Missing 22 0.1 9 0.1 19 0.1 9 0.1
Infection and inflammation during 
pregnancy
2216 13.3 1244 9.2 1834 13.4 1044 9.3
Missing 2 0.0 2 0.0 1 0.0 1 0.0
Mother use of aspirin during pregnancy 1347 8.1 1005 7.5 1096 8.0 858 7.6
Mother use of ibuprofen during pregnancy 990 5.9 553 4.1 840 6.1 447 4.0
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Table 2. Adjusted differences for body mass index (BMI) z scores and waist circumference at age 7 and 11 according to maternal 
acetaminophen use during pregnancy
BMI z scores 
at 7 years 
Waist circumference 
(cm) at 7 years
BMI z scores 
at 11 years 
Waist 
circumference 
(cm) at 11 years
Acetaminophen use during 
pregnancy 
No. of 
children
Adjusted difference and 95% CI a
No. of 
children
Adjusted difference and 95% CI a
Among girls 
    Never use 6446 reference reference 5499 reference reference
    Ever use 8062 0.02 (-0.01, 0.05) -0.03 (-0.20, 0.14) 6951 0.01 (-0.02, 0.05) 0.21 (-0.07, 0.49)
       Timing specific b
       1st trimester only 1424 0.02 (-0.01, 0.05) 0.19 (-0.10, 0.48) 1227 0.01 (-0.05, 0.07) 0.13 (-0.33, 0.59)
       2nd trimester only 752 0.05 (-0.01, 0.10) -0.16 (-0.53, 0.20) 676 0.07 (-0.01, 0.14) 0.31 (-0.30, 0.93)
       3rd trimester only 1548 0.02 (-0.05, 0.09) -0.11 (-0.40, 0.18) 1379 0.00 (-0.06, 0.06) 0.19 (-0.29, 0.66)
       any 2 trimesters 2118 0.02 (-0.03, 0.07) -0.03 (-0.29, 0.23) 1827 0.00 (-0.05, 0.05) 0.20 (-0.22, 0.62)
       all three trimesters 1508 -0.00 (-0.05, 0.04) 0.11 (-0.19, 0.42) 1256 0.01 (-0.05, 0.08) 0.33 (-0.20, 0.85)
Among boys 
    Never use 7037 reference reference 5754 reference reference
    Ever use 8582 -0.03 (-0.06, 0.00) -0.25 (-0.41, -0.10) 6730 -0.04 (-0.07, 0.00) -0.22 (-0.50, 0.07)
       Timing specific b
       1st trimester only 1583 -0.05 (-0.10, 0.00) -0.39 (-0.65, -0.13) 1279 -0.03 (-0.09, 0.03) -0.12 (-0.60, 0.37)
       2nd trimester only 768 0.01 (-0.06, 0.08) -0.32 (-0.68, 0.04) 629 -0.05 (-0.13, 0.03) -0.02 (-0.68, 0.64)
       3rd trimester only 1685 -0.05 (-0.10, -0.00) -0.25 (-0.51, 0.01) 1282 -0.07 (-0.13, -0.01) -0.35 (-0.85, 0.15)
       any 2 trimesters 2308 -0.05 (-0.09, -0.01) -0.26 (-0.49, -0.03) 1810 -0.04 (-0.09, 0.02) -0.28 (-0.70, 0.13)
       all three trimesters 1488 -0.01 (-0.07, 0.04) -0.13 (-0.41, 0.15) 1142 -0.01 (-0.08, 0.05) -0.09 (-0.62, 0.45)
a Adjusted maternal age, parity, birth year, parental socio-occupational status, maternal pre-pregnancy body mass index, maternal alcohol drinking 
during pregnancy, maternal smoking during pregnancy, maternal musculoskeletal diseases and pain, fever, or infection/inflammation during 
pregnancy, maternal use of ibuprofen and aspirin during pregnancy. b Timing of exposure analyses included all never users and approximately 91.5% 
acetaminophen users who indicated their timing of use.   
Table 3. Risk ratios for overweight at age 7 and 11 years according to maternal acetaminophen use during pregnancy
Overweight at age 7 years Overweight at age 11 yearsAcetaminophen use 
during pregnancy 
No. of 
children
N Adjusted RR and 95% CI a
No. of 
children
N Adjusted RR and 95% CI a
Among girls 
    Never use 6446 694 reference 5499 404 reference
    Ever use 8062 960 0.99 (0.91, 1.09) 6951 660 1.10 (0.97, 1.24)
       Timing specific b
       1st trimester only 1424 174 1.07 (0.92, 1.25) 1227 107 1.10 (0.90, 1.34)
       2nd trimester only 752 82 0.96 (0.77, 1.19) 676 61 1.10 (0.85, 1.41)
       3rd trimester only 1548 186 0.99 (0.85, 1.15) 1379 121 1.01 (0.84, 1.23)
       any 2 trimesters 2118 245 0.95 (0.83, 1.09) 1827 171 1.05 (0.88, 1.24)
       all three trimesters 1508 189 0.99 (0.86, 1.15) 1256 152 1.31 (1.10, 1.56)
Among boys 
    Never use 7037 555 reference 5754 465 reference
    Ever use 8582 802 1.02 (0.92, 1.14) 6730 658 1.03 (0.92, 1.16)
       Timing specific b
       1st trimester only 1583 137 1.02 (0.86, 1.22) 1279 118 1.10 (0.91, 1.32)
       2nd trimester only 768 70 1.04 (0.82, 1.31) 629 59 1.05 (0.82, 1.35)
       3rd trimester only 1685 155 1.02 (0.86, 1.21) 1282 108 0.95 (0.78, 1.16)
       any 2 trimesters 2308 207 0.97 (0.83, 1.14) 1810 178 1.04 (0.88, 1.22)
       all three trimesters 1488 157 1.05 (0.88, 1.25) 1142 136 1.06 (0.86, 1.29)
a Adjusted maternal age, parity, birth year, parental socio-occupational status, maternal pre-pregnancy body mass index, maternal 
alcohol drinking during pregnancy, maternal smoking during pregnancy, maternal musculoskeletal diseases and pain, fever, or 
infection/inflammation during pregnancy, maternal use of ibuprofen and aspirin during pregnancy. b Timing of exposure analyses 
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included all never users and approximately 91.5% acetaminophen users who indicated their timing of use.   
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Table 4.  Risk ratios for overweight at age 7 and 11 years according to maternal acetaminophen use during pregnancy, excluding mothers with specific 
health conditions during pregnancy.
Overweight in girls Overweight in boys 
Age 7 Age 11 Age 7 Age 11
Acetaminophen use during pregnancy 
N
Adjusted RR 
and 95% CI a
N
Adjusted RR
 and 95% CI a
N
Adjusted RR 
and 95% CI a
N
Adjusted RR 
and 95% CI a
Among mothers without fever during pregnancy
    Never used 550 Reference 322 Reference 423 Reference 356 Reference
    Ever used 610 0.96 (0.88, 1.06) 418 1.09 (0.96, 1.23) 537 1.00 (0.92, 1.09) 451 1.05 (0.95, 1.17)
        in all three trimesters 123 1.00 (0.86, 1.17) 90 1.34 (1.11, 1.63) 96 1.00 (0.86, 1.17) 92 1.06 (0.87, 1.28)
        >20 weeks 57 0.89 (0.71, 1.11) 47 1.55 (1.22, 1.97) 46 1.06 (0.85, 1.32) 48 1.04 (0.77, 1.39)
        p-trend for cumulative week of exposure
0.68 <.001 0.49 0.74
Among mothers without infections or inflammations 
during pregnancy
    Never used 630 Reference 360 Reference 506 Reference 417 Reference
    Ever used 835 1.01 (0.93, 1.10) 574 1.18 (1.06, 1.33) 702 0.95 (0.87, 1.02) 571 1.04 (0.95, 1.15)
        in all three trimesters 163 1.01 (0.87, 1.16) 125 1.46 (1.23, 1.73) 137 0.91 (0.79, 1.04) 117 1.01 (0.85, 1.20)
        >20 weeks 70 0.86 (0.69, 1.06) 59 1.47 (1.17, 1.84) 73 0.96 (0.79, 1.16) 61 1.01 (0.78, 1.32)
        p-trend for cumulative week of exposure
0.2145 <.001 0.58 0.85
Among mothers without musculoskeletal diseases 
during pregnancy
    Never used 623 Reference 372 Reference 503 Reference 425 Reference
    Ever used 827 1.01 (0.93, 1.10) 557 1.11 (0.99, 1.25) 676 0.97 (0.89, 1.05) 548 1.00 (0.90, 1.10)
        in all three trimesters 148 0.97 (0.84, 1.13) 114 1.35 (1.14, 1.61) 129 0.95 (0.82, 1.09) 109 1.00 (0.84, 1.21)
        >20 weeks 64 0.86 (0.69, 1.06) 52 1.34 (1.06, 1.71) 66 1.00 (0.82, 1.22) 60 1.06 (0.81, 1.38)
        p-trend for cumulative week of exposure 0.2378 <.001 0.91 0.58
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a Adjusted maternal age, parity, birth year, parental socio-occupational status, maternal pre-pregnancy body mass index, maternal alcohol drinking during 
pregnancy, maternal smoking during pregnancy, maternal musculoskeletal diseases and pain, fever, or infection/inflammation during pregnancy, maternal use of 
ibuprofen and aspirin during pregnancy.
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Figure 1. Risk ratios for overweight in children according to cumulative weeks of acetaminophen use during pregnancy. Model adjusted for 
maternal age, parity, birth year, parental socio-occupational status, maternal pre-pregnancy body mass index, maternal alcohol drinking during pregnancy, 
maternal smoking during pregnancy, maternal musculoskeletal diseases and pain, fever, or infection/inflammation during pregnancy, maternal use of 
ibuprofen and aspirin during pregnancy. P-trend was calculated using linear trend tests by fitting weeks of exposure as a continuous variable.  
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Figure 1. Risk ratios for overweight in children according to cumulative weeks of acetaminophen use during pregnancy. Model adjusted for 
maternal age, parity, birth year, parental socio-occupational status, maternal pre-pregnancy body mass index, maternal alcohol drinking during pregnancy, 
maternal smoking during pregnancy, maternal musculoskeletal diseases and pain, fever, or infection/inflammation during pregnancy, maternal use of 
ibuprofen and aspirin during pregnancy. P-trend was calculated using linear trend tests by fitting weeks of exposure as a continuous variable.  
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